This development is part of Botanix’s strategy to expand payer coverage, now reaching over 110 million commercial lives, for its novel treatment targeting primary axillary hyperhidrosis, a condition ...

The company's FDA-approved drug Sofdra is the first for the common and embarrassing condition of excessive sweating.

Dermatology drugmaker Journey Medical has trekked its Dr. Reddy’s Laboratories-partnered rosacea med across the FDA finish line as Emrosi. | The drug proved superiority in clearing lesions over ...

Botanix Pharmaceuticals Limited (AU:BOT) has released an update. Botanix Pharmaceuticals Limited is set to make waves in the dermatology market ...

Botox is one of the significant advances in dealing with hyperhidrosis: a practical, noninvasive, and long-term solution to a situation that, properly allowed to develop, can adversely affect ...